Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07024784 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies
A Phase 2 study of Fallopian Tube Cancer and Gynecologic Cancers, sponsored by AbbVie.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 377
- Enrollment target
- 10
- Study locations
NCT07024784: Recruiting Phase 2 study of Fallopian Tube Cancer and Gynecologic Cancers, sponsored by AbbVie.
NCT07024784 is a Phase 2 study of Fallopian Tube Cancer and Gynecologic Cancers that is actively recruiting participants, run by AbbVie. The registered enrollment target is 377 participants, above the 251-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (50% higher). The trial reports 10 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07024784, a Phase 2 study of Fallopian Tube Cancer and Gynecologic Cancers, is actively recruiting participants, sponsored by AbbVie.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 377 participants
- Enrollment target
- 10
- Study locations
Study Summary
Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other anti-cancer therapies in adult participants with gynecologic cancers. IMGN151 is an investigational drug being developed for the treatment of gynecologic cancers. Participants are placed in 1 of 4 groups, called treatment arms. Each group receives a different treatment. Around 377 participants with gynecologic cancers will be enrolled in the study at approximately 50 sites worldwide. Participants will receive intravenous infusions of IMGN151 as monotherapy or in combination with anti-cancer therapies according to their assigned study arm. In Arm A, participants will receive IMGN151 in combination with carboplatin on Day 1 of each cycle. In Arm B, participants will receive IMGN151 in combination with olaparib, twice a day (BID) on Day 1 of each cycle. In Arm C, participants will receive IMGN151 in combination with bevacizumab on Day 1 of each cycle. In Arm D, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm E, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. In Arm F, participants will receive IMGN151 as monotherapy on Day 1 of each cycle. The total study duration will be approximately 3 years. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and scans.
Primary Outcome
Dose limiting toxicities (DLTs) of IMGN151 when given as monotherapy and in combination with other anti-cancer therapies DLT events are defined as clinically significant adverse events or abnormal laboratory values assessed as unrelated to disease progression, underlying disease, intercurrent illness, or concomitant medications.
Conditions Studied
Interventions
- DRUG Bevacizumab
- DRUG Carboplatin
- DRUG Olaparib
- DRUG IMGN151
Study Locations (10)
Tel Aviv
- The Chaim Sheba Medical Center /ID# 275997 - Ramat Gan
- Tel Aviv Sourasky Medical Center /ID# 275852 - Tel Aviv
Other
- Rambam Health Care Campus- Haifa /ID# 276004 - Haifa
- Shaare Zedek Medical Center /ID# 275854 - Jerusalem
Tokyo
- National Cancer Center Hospital /ID# 276715 - Chuo-Ku
- The Cancer Institute Hospital Of JFCR /ID# 276711 - Koto-ku
New Jersey
- Holy Name Medical Center /ID# 279017 - Teaneck
Rhode Island
- Women & Infants Hospital /ID# 277930 - Providence
Central District
- Rabin Medical Center /ID# 279142 - Petah Tikva
Hyōgo
- Hyogo Cancer Center /ID# 276940 - Akashi-shi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 377 participants |
| Start Date | 2025-07-30 |
| Est. Completion | 2028-02 |
| Phase | Phase 2 |
What NCT07024784 shows while recruiting
NCT07024784 is an interventional study that assigns participants to a tested intervention. The registered 377 participants enrollment target is mid-sized for trials with a published cap, above the 251-participant average among 85 other Fallopian Tube Cancer trials with a reported enrollment target (50% higher).
The record links to 4 conditions, with Fallopian Tube Cancer appearing as the primary indexed condition, and to 4 interventions - of which Bevacizumab is the first listed.
NCT07024784 lists 10 locations in 7 states (Tel Aviv, Other, Tokyo).
Frequently Asked Questions
What is clinical trial NCT07024784 about?
NCT07024784 is a clinical study titled "A Study to Assess Change in Disease Activity and Adverse Events in Adult Participants With Gynecologic Cancers Receiving Intravenous Infusion of IMGN151 as Monotherapy or in Combination With Other Therapies". Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess safety and tolerability of IMGN151 when given as monotherapy and in combination with other anti-cancer therapies in adult participants with gynecologic cancers. IMG...
What is the current status of trial NCT07024784?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 377 participants. The study started on 2025-07-30. Estimated completion is 2028-02.
What conditions does trial NCT07024784 study?
This clinical trial studies the following conditions: Fallopian Tube Cancer, Gynecologic Cancers, Platinum-sensitive Ovarian Cancer, Primary Peritoneal Cancer (PSOC).
What interventions are being tested in trial NCT07024784?
The interventions under investigation include: Bevacizumab (DRUG), Carboplatin (DRUG), Olaparib (DRUG), IMGN151 (DRUG).
Who is sponsoring clinical trial NCT07024784?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07024784 being conducted?
This trial has 10 study locations across New Jersey, Rhode Island, Central District, Tel Aviv, Hyōgo. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fallopian Tube Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07024784's enrollment target sits among peer trials
377 16th of 85 higher than 70 of 85 other Fallopian Tube Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fallopian Tube Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
RECRUITING · Phase 2
-
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
RECRUITING · Phase 2
-
A Study to Assess Anti-Tumor Activity of Intravenously (IV) Infused Carboplatin With Mirvetuximab Soravtansine in Participants With Newly Diagnosed Folate Receptor Alpha (FRα)Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer.
RECRUITING · Phase 2
-
CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.
RECRUITING · Phase 2
-
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04254185 · 378 participants · NA
Clinical Trial for Surgery of the Ulnar Nerve (SUN) at the Elbow
- NCT06616584 · 378 participants · Phase 2
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
- NCT03102125 · 376 participants · Phase 4
Allograft Dysfunction in Heart Transplant
- NCT05055297 · 376 participants · NA
SELUTION4BTK Trial
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI